Bempedoic acid

• Description :

  Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor[1]. Bempedoic acid (ETC-1002) activates AMPK[2].

• Product Name Alternative :

  ETC-1002; ESP-55016

• UNSPSC :

  12352211

• Hazard Statement :

  H302, H312, H332

• Target :

  AMPK; ATP Citrate Lyase

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/ETC-1002.html

• Concentration :

  10mM

• Purity :

  99.97

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(O)C(C)(C)CCCCCC(O)CCCCCC(C)(C)C(O)=O

• Molecular Formula :

  C19H36O5

• Molecular Weight :

  344.49

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Pinkosky SL, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54 (1) :134-51.|[2]Filippov S, et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013 Aug;54 (8) :2095-108.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  AMPK

• CAS Number :

  [738606-46-7]